Events

Back

PROMETHERA BIOSCIENCES ANNOUNCES LATE-BREAKING DATA PRESENTATION

August 14th - 29th 2019

Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure. Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure. Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure.

14.08.2019 - 29.07.2021 / 7:00 > 12:00 PM ULiège - UMONS

FIND MORE INFO & REGISTER HERE